Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 12/2010

01-12-2010 | Brief report

The prevalence of human papillomavirus infection in Mombasa, Kenya

Authors: Hugo De Vuyst, Maria Rita Parisi, Andrew Karani, Kishor Mandaliya, Lucy Muchiri, Salvatore Vaccarella, Marleen Temmerman, Silvia Franceschi, Flavia Lillo

Published in: Cancer Causes & Control | Issue 12/2010

Login to get access

Abstract

Objectives

A human papillomavirus (HPV) prevalence survey was done in Mombasa, Kenya, to improve the knowledge of HPV prevalence and genotype distribution in sub-Saharan African countries overall, and in women of different ages.

Methods

HPV prevalence was assessed using PCR in women older than 15 years attending family planning and mother–child care services.

Results

Among 496 women, HPV prevalence was high (42.3%; 95% CI: 37.9–46.8; world age-standardized). Moreover, 46% of HPV-positive women harbored multiple-type infections. The most common types were HPV58 (10.5% of women), HPV16 (7.7%), HPV53 (6.7%), HPV18 (4.6%), and HPV6 (4.4%), and the prevalence of any high-risk HPV type was 28.8%. HPV prevalence was elevated among all age-groups (range 36.4–45.7%). Independent associations with HPV positivity were found for being in a polygamous marriage (OR = 1.7) and lifetime number of sexual partners (OR for ≥3 vs. 1 = 1.5), although they were of only borderline statistical significance.

Conclusions

These findings differ from other world regions, showing a high HPV burden in all age-groups with a high proportion of multiple-type infections. Our data strengthen the urgency of HPV vaccination in Kenya but also highlight the elevated number of women who would have positive results in an HPV-based screening program in the country.
Literature
1.
Curado MP, Edwards B, Shin HR et al. (2007) Cancer incidence in five continents, Vol. IX. IARC Scientific Publication No. 160. IARC, Lyon
2.
de Sanjose S, Diaz M, Castellsague X et al (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7:453–459CrossRefPubMed
3.
Franceschi S, Herrero R, Clifford GM et al (2006) Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119:2677–2684CrossRefPubMed
4.
de Vuyst H, Lillo F, Broutet N, Smith JS (2008) HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 17:545–554CrossRefPubMed
5.
Denny L, Quinn M, Sankaranarayanan R (2006) Chapter 8: screening for cervical cancer in developing countries. Vaccine 24(Suppl 3):S3-71–S3-77
6.
Louie KS, de Sanjose S, Mayaud P (2009) Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health 14:1287–1302CrossRefPubMed
7.
De Vuyst H, Claeys P, Njiru S et al (2005) Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography. Int J Gynaecol Obstet 89:120–126CrossRefPubMed
8.
Muňoz N, Bosch FX, de Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527CrossRefPubMed
9.
Thomas JO, Herrero R, Omigbodun AA et al (2004) Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 90:638–645CrossRefPubMed
10.
Keita N, Clifford GM, Koulibaly M et al (2009) HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 101:202–208CrossRefPubMed
11.
De Vuyst H, Steyaert S, Van Renterghem L et al (2003) Distribution of human papillomavirus in a family planning population in Nairobi, Kenya. Sex Transm Dis 30:137–142CrossRefPubMed
12.
Castellsague X, Menendez C, Loscertales MP et al (2001) Human papillomavirus genotypes in rural Mozambique. Lancet 358:1429–1430CrossRefPubMed
13.
Gravitt PE, Kamath AM, Gaffikin L, Chirenje ZM, Womack S, Shah KV (2002) Human papillomavirus genotype prevalence in high-grade squamous intraepithelial lesions and colposcopically normal women from Zimbabwe. Int J Cancer 100:729–732CrossRefPubMed
14.
Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC (2000) Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 92:818–825CrossRefPubMed
15.
Wall SR, Scherf CF, Morison L et al (2005) Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. Br J Cancer 93:1068–1076CrossRefPubMed
16.
Xi LF, Toure P, Critchlow CW et al (2003) Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer 103:803–809CrossRefPubMed
17.
De Vuyst H, Clifford G, Li N, Franceschi S (2009) HPV infection in Europe. Eur J Cancer 45:2632–2639CrossRefPubMed
18.
Baay MF, Kjetland EF, Ndhlovu PD et al (2004) Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. J Med Virol 73:481–485CrossRefPubMed
19.
Womack SD, Chirenje ZM, Gaffikin L et al (2000) HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 85:206–210PubMed
20.
Serwadda D, Wawer MJ, Shah KV et al (1999) Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. J Infect Dis 180:1316–1319CrossRefPubMed
21.
Said HM, Ahmed K, Burnett R, Allan BR, Williamson AL, Hoosen AA (2009) HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community-based microbicide study in Pretoria, South Africa. J Clin Virol 44:318–321CrossRefPubMed
22.
23.
Clifford GM, Goncalves MA, Franceschi S, For the HPV and HIV Study Group (2006) Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20:2337–2344CrossRefPubMed
24.
Galan-Sanchez F, Rodriguez-Iglesias MA (2009) Comparison of human papillomavirus genotyping using commercial assays based on PCR and reverse hybridization methods. APMIS 117:708–715CrossRefPubMed
25.
Vaccarella S, Franceschi S, Herrero R et al (2006) Sexual behavior, condom use and HPV: pooled analysis of the International Agency for Research on Cancer HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 15:326–333CrossRefPubMed
26.
Arbyn M, Dillner J, Schenck U et al (2008) Methods for screening and diagnosis. In: Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, Daniel J, von Karsa L (eds) European guidelines for quality assurance in cervical cancer screening, 2nd edn. Office for Official Publications of the European Communities, Luxemburg, pp 69–152
Metadata
Title
The prevalence of human papillomavirus infection in Mombasa, Kenya
Authors
Hugo De Vuyst
Maria Rita Parisi
Andrew Karani
Kishor Mandaliya
Lucy Muchiri
Salvatore Vaccarella
Marleen Temmerman
Silvia Franceschi
Flavia Lillo
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9645-z

Other articles of this Issue 12/2010

Cancer Causes & Control 12/2010 Go to the issue

Original paper

Breast cancer screening interventions in selected counties across US regions

Original paper

Light at night and breast cancer risk: results from a population-based case–control study in Connecticut, USA

Original paper

Comprehensive cancer control: progress and accomplishments

Original paper

Association between human papillomavirus and adenocarcinoma of rectum and recto-sigmoid junction: a cohort study of 10,612 women in Taiwan

Original paper

Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case–control study

Original paper

The CCC National Partnership: an example of organizations collaborating on comprehensive cancer control
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits